目的 評價2010-2015年天津市腫瘤醫(yī)院植物來源的抗腫瘤藥及其衍生物類藥物使用情況。方法 對2010-2015年植物來源的抗腫瘤藥及其衍生物類藥物的用量、銷售金額、用藥頻度（DDDs）、日均藥費（DDC）和藥品排序比（B/A）進行統(tǒng)計和分析。結(jié)果 紫杉醇類的使用金額占植物來源的抗腫瘤藥及其衍生物類藥物的85%以上，同時增長勢頭強勁；鬼臼毒素類的使用金額占比最低，只有1%左右，而且使用金額從2012年以后逐年下降。植物來源的抗腫瘤藥及其衍生物類藥物的總使用金額是逐年增長的趨勢，但2012年以后增幅較小。伊立替康、依托泊苷和長春地辛的使用金額呈逐年遞增。從排序來看，紫杉醇、多西他賽、伊立替康和長春瑞濱連續(xù)6年排名前4位?？侱DDs逐年增長，多西他賽的DDDs排名持續(xù)居于首位，紫杉醇居于次席。DDC和排序相對穩(wěn)定，2010-2014年伊立替康的DDC排名持續(xù)居于首位，紫杉醇在2015年躍升至第1位。其中長春新堿的DDC最低，伊立替康的DDC最高。DDC超過100元的是伊立替康、紫杉醇、多西他賽和長春瑞濱。多西他賽的B/A最大，連續(xù)6年為2.00，紫杉醇的B/A連續(xù)6年均為0.50；替尼泊苷、長春新堿和長春地辛的B/A均接近1.00。結(jié)論 天津市腫瘤醫(yī)院植物來源的抗腫瘤藥及其衍生物類藥物的應(yīng)用基本合理，但仍存在一些不足，還需進一步加強管理。

Objective To investigate the utilization of antineoplastic agents from plant source and its derivatives in Tianjin Cancer Hospital from 2010 to 2015. Methods The utilization information of antineoplastic agents from plant source and its derivatives in Tianjin Cancer Hospital from 2010 to 2015 was extracted, and the consumption sum, defined daily doses (DDDs), defined daily cost (DDC), and drug sequence ratio (B/A) were analyzed statistically. Results The consumption sums of Paclitaxel in each year accounted for more than 85% in all and increased year by year. The consumption sums of podophyllotoxins accounted for the lowest, only about 1%, and the consumption sums decreased year by year since 2012. From 2010 to 2015, the total consumption sums of antineoplastic agents from plant source and its derivatives were increased year by year, but the increase was smaller after 2012. The consumption sums of irinotecan, etoposide, and vindesin were increased year by year. From the terms of sequences, paclitaxel, docetaxel, irinotecan, and vindesin ranked the top 4 in 6 consecutive years. The total DDDs increased year by year, and DDDs of docetaxel ranked in the first place, and paclitaxel were in the second place. In addition, DDC and sequences were relatively stable. DDC of irinotecan sustained in the first place from 2010 to 2014, but paclitaxel ranked the first place in 2015. The lowest and highest DDC were vincristine and irinotecan, respectively. DDC of irinotecan, paclitaxel, docetaxel, and vinorelbine were above 100 Yuan. B/A of docetaxel and paclitaxel were 2.00 and 0.5 from 2010 to 2015, but those of teniposide, vincristine, and vindesin were close to 1.00. Conclusion The utilization of antineoplastic agents from plant source and its derivatives in Tianjin Cancer Hospital is rational on the whole, but there are still some problems, which needs further efforts to strengthen the management.